Information  X 
Enter a valid email address

Tiziana Life Sci PLC (TILS)

  Print      Mail a friend

Thursday 07 June, 2018

Tiziana Life Sci PLC

Appointment of Broker

RNS Number : 5685Q
Tiziana Life Sciences PLC
07 June 2018
 

7 June 2018

 

Tiziana Life Sciences plc

(the "Company" or "Tiziana")

 

Appointment of Broker

 

 

Tiziana Life Sciences plc (AIM: TILS), a clinical stage biotechnology company developing targeted drugs for cancer and autoimmune diseases, announces that it has appointed Stockdale Securities Limited as its broker, with immediate effect.

 

Cairn Financial Advisers LLP, who were acting as broker on an interim basis, will cease to act as the Company's broker with immediate effect and will continue to act as the Company's Nominated Adviser.

 

Contacts

 

Tiziana Life Sciences plc

Gabriele Cerrone, Chairman and founder                               +44 (0)20 7493 2853

 

 

Cairn Financial Advisers LLP (Nominated Adviser)

Liam Murray / Jo Turner                                                          +44 (0)20 7213 0880

 

 

Stockdale Securities Limited (Broker)

Andy Crossley/ Antonio Bossi / Owen Matthews                    +44 (0)20 7601 6100

 

 

 

About Tiziana

 

Tiziana is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The Company is focused on its lead compound milciclib. The Company is also in clinical development of foralumab. Foralumab is the only fully human engineered human anti-CD3 antibody in clinical development. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBS), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.

 

For more information go to http://www.tizianalifesciences.com 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
APPUNRBRWSANRAR

a d v e r t i s e m e n t